Literature DB >> 16159928

Distribution of fluoroquinolone MICs in Helicobacter pylori strains from Korean patients.

Jung Mogg Kim1, Joo Sung Kim, Nayoung Kim, Hyun Chae Jung, In Sung Song.   

Abstract

OBJECTIVES: The aim of this study was to assess the prevalence rate of primary fluoroquinolone resistance in Helicobacter pylori isolates from Korean patients over the past 16 years.
METHODS: One hundred and thirty-five strains of H. pylori (34 strains in 1987, 36 in 1994 and 65 in 2003) were isolated from antral gastric mucosal biopsy specimens. The determination of MICs for the H. pylori isolates of ciprofloxacin, levofloxacin and moxifloxacin was examined by using the serial 2-fold agar dilution method. DNA sequences of the gyrA gene in fluoroquinolone-resistant strains were determined.
RESULTS: The distribution of fluoroquinolone MICs (ciprofloxacin, levofloxacin and moxifloxacin) shifted to higher concentrations during 1987-2003. All of the levofloxacin- or moxifloxacin-resistant strains were resistant to ciprofloxacin. Sequence analysis in fluoroquinolone-resistant strains showed point mutation of the gyrA gene at A272G and G271A, indicating mutations of the codon Asp-91 in the fluoroquinolone-resistance-determining region of the DNA gyrase.
CONCLUSIONS: These results suggest that resistance to fluoroquinolones has been increasing in the Korean population and the resistance is most likely mediated through point mutation in gyrA.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16159928     DOI: 10.1093/jac/dki334

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  32 in total

1.  Distribution of gyrA mutations in fluoroquinolone-resistant Helicobacter pylori strains.

Authors:  Li-Hui Wang; Hong Cheng; Fu-Lian Hu; Jiang Li
Journal:  World J Gastroenterol       Date:  2010-05-14       Impact factor: 5.742

2.  Genotypic resistance in Helicobacter pylori strains correlates with susceptibility test and treatment outcomes after levofloxacin- and clarithromycin-based therapies.

Authors:  Jyh-Ming Liou; Chi-Yang Chang; Wang-Huei Sheng; Yu-Chi Wang; Mei-Jyh Chen; Yi-Chia Lee; Hsu-Wei Hung; Hung Chian; San-Chun Chang; Ming-Shiang Wu; Jaw-Town Lin
Journal:  Antimicrob Agents Chemother       Date:  2010-12-28       Impact factor: 5.191

3.  Alaska sentinel surveillance study of Helicobacter pylori isolates from Alaska Native persons from 2000 to 2008.

Authors:  Adrienne H Tveit; Michael G Bruce; Dana L Bruden; Julie Morris; Alisa Reasonover; Debby A Hurlburt; Thomas W Hennessy; Brian McMahon
Journal:  J Clin Microbiol       Date:  2011-08-03       Impact factor: 5.948

4.  Search for novel candidate mutations for metronidazole resistance in Helicobacter pylori using next-generation sequencing.

Authors:  Tran Thanh Binh; Rumiko Suzuki; Tran Thi Huyen Trang; Dong Hyeon Kwon; Yoshio Yamaoka
Journal:  Antimicrob Agents Chemother       Date:  2015-02-02       Impact factor: 5.191

5.  Quinolone resistance in Helicobacter pylori isolates in Germany.

Authors:  Erik Glocker; Hans-Peter Stueger; Manfred Kist
Journal:  Antimicrob Agents Chemother       Date:  2006-10-16       Impact factor: 5.191

6.  Who's Winning the War? Molecular Mechanisms of Antibiotic Resistance in Helicobacter pylori.

Authors:  Kathleen R Jones; Jeong-Heon Cha; D Scott Merrell
Journal:  Curr Drug ther       Date:  2008-09-01

7.  In vitro activity of nemonoxacin, tigecycline, and other antimicrobial agents against Helicobacter pylori isolates in Taiwan, 1998-2007.

Authors:  J-C Yang; P-I Lee; P-R Hsueh
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-07-25       Impact factor: 3.267

Review 8.  Levofloxacin/amoxicillin-based schemes vs quadruple therapy for Helicobacter pylori eradication in second-line.

Authors:  Simona Di Caro; Lucia Fini; Yayha Daoud; Fabio Grizzi; Antonio Gasbarrini; Antonino De Lorenzo; Laura Di Renzo; Sara McCartney; Stuart Bloom
Journal:  World J Gastroenterol       Date:  2012-10-28       Impact factor: 5.742

9.  Second-line treatment for Helicobacter pylori infection based on moxifloxacin triple therapy: a randomized controlled trial.

Authors:  Josip Bago; Branko Pevec; Monika Tomić; Marinko Marusić; Vinko Bakula; Petra Bago
Journal:  Wien Klin Wochenschr       Date:  2009       Impact factor: 1.704

10.  Evaluation of a new test, genotype HelicoDR, for molecular detection of antibiotic resistance in Helicobacter pylori.

Authors:  Emmanuelle Cambau; Vera Allerheiligen; Céline Coulon; Céline Corbel; Christine Lascols; Lionel Deforges; Claude-James Soussy; Jean-Charles Delchier; Francis Megraud
Journal:  J Clin Microbiol       Date:  2009-09-16       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.